First Squawk(@FirstSquawk):MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH SCIBRUNCH THERAPEUTICS FOR SPR2015, AN INVESTIGATIONAL ORAL KRAS G12D (ON) INHIBITOR (DESIGNED TO BLOCK THE KRAS G12D GENE MUTATION THAT CAUSES TUMOURS TO GROW IN CANCERS LIKE PANCREATIC AND COLORECTAL CANCER)

First Squawk

@FirstSquawk

Firstsquawk Is a Global Financial (News) Squawk Service Specialising In Financial Markets, Macro, Geopolitics,politics

Joined July 2015

251 Following 568.3K Followers

First Squawk@FirstSquawk

4hours ago

MERCK ENTERS INTO EXCLUSIVE GLOBAL LICENSE AGREEMENT WITH SCIBRUNCH THERAPEUTICS FOR SPR2015, AN INVESTIGATIONAL ORAL KRAS G12D (ON) INHIBITOR (DESIGNED TO BLOCK THE KRAS G12D GENE MUTATION THAT CAUSES TUMOURS TO GROW IN CANCERS LIKE PANCREATIC AND COLORECTAL CANCER)